Sulfonylureas and glinides are usually avoided due to the risk of hypoglycemia, as are incretin-based therapies (DPP4 inhibitors and GLP-1 analogs) due to underlying pancreatic disease. The gene discussed is DPP4; the disease is pancreas disorder.